Ibuprofen is as effective as paracetamol (acetaminophen) as an antipyretic and analgesic agent in paediatric patients. Ibuprofen is considered to be well tolerated; however, there are reports on gastrointestinal bleeding or renal adverse effects among children treated with ibuprofen. Oral ibuprofen suspension was recently registered and approved by the Ministry of Health in Israel as an antipyretic and analgesic agent. Before distribution of the drug to pharmacies, we aimed to follow possible adverse effects among children receiving ibuprofen suspension in several paediatric wards and clinics. Children with fever needing antipyretic medication received ibuprofen oral suspension 5 to 10 mg/kg/dose. In each case the age of the patient, gender, diagnosis, number of ibuprofen doses, duration of treatment and any adverse reactions were reported. 1564 children from 14 paediatric wards (11 hospitals) and from five paediatric and family clinics participated in the study; 882 males and 682 females. The patients, aged 3.6 ± 4.2 years (range 1 month to 16.5 years), received 2.4 ± 3 (range 1 to 22) doses of ibuprofen suspension for 1.56 ± 2.11 (range 1 to 20) days. Adverse reactions were reported among 26 patients (1.66%) [95% confidence interval (CI) 1.1–2.4]; 18 children (1.15%) [95% CI 0.7–1.8] vomited immediately after the administration of the drug and it was not readministered. Two children (0.12%) [95% CI 0.02–0.46] had abdominal pain that resolved spontaneously, two patients reported nausea, and two other children had diarrhoea. Eight children (0.51%) reported experiencing a ‘bitter taste’ from the medication, of whom one patient discontinued the medication while the other seven continued it. The adverse reactions following administration of oral ibuprofen suspension reported in our study were low in frequency, mild and disappeared spontaneously. However, continuing reporting on its tolerability is needed.
布洛芬在小儿患者中作为退烧和止痛药与
对乙酰氨基酚(
扑热息痛)同样有效。
布洛芬被认为耐受性良好,然而,有报道显示在接受
布洛芬治疗的儿童中可能出现胃肠道出血或肾脏不良反应。以口服
布洛芬悬液的形式,最近在以色列卫生部注册并批准作为退烧和止痛药。在将该药物分发至药房之前,我们旨在跟踪在多个儿科病房和门诊接受
布洛芬悬液治疗的儿童可能出现的不良反应。需要使用退烧药的发热儿童接受5至10 mg/kg/剂量的口服
布洛芬悬液。在每个案例中,报告了患者的年龄、性别、诊断、
布洛芬剂量次数、治疗持续时间及任何不良反应。共有1564名儿童参与了研究,来自14个儿科病房(11家医院)和5个儿科及家庭诊所;其中882名为男性,682名为女性。患者年龄为3.6 ± 4.2岁(范围1个月至16.5岁),使用
布洛芬悬液的剂量为2.4 ± 3(范围1至22)剂,疗程为1.56 ± 2.11(范围1至20)天。26名患者(1.66%)报告出现不良反应[95%置信区间(CI)1.1–2.4];18名儿童(1.15%)[95% CI 0.7–1.8]在用药后立即呕吐,且未再次给予药物。两名儿童(0.12%)[95% CI 0.02–0.46]出现腹痛,但自发缓解,另有两名患者报告恶心,还有两名儿童出现腹泻。八名儿童(0.51%)报告服用药物后体验到“苦味”,其中一名患者停止用药,而其他七名继续用药。我们研究中报告的口服
布洛芬悬液的不良反应发生率较低,症状轻微且自发消失。然而,仍需持续报告其耐受性。